Do you want to read an article? Please log in or register.
Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease
Cardiovascular Risk and Diseases
Related content
Cardiovascular Risk and Diseases
The association between stress-induced hyperglycemia ratio and cardiovascular events as well as all-cause mortality in patients with chronic kidney disease and diabetic nephropathy
Cardiovasc Diabetol
Cao B, Guo Z, Li DT, Zhao LY, Wang Z, Gao YB, Wang YX
doi: 10.1186/s12933-025-02610-1
COMMENTED
Cardiovascular Risk and Diseases
Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, Eriksson JW
doi: 10.1016/S2213-8587(25)00165-2
ESC 2025
Heart Failure
VICTOR: Vericiguat lowers the risk of cardiovascular and all-cause death in patients with heart failure
Cardiovascular Risk and Diseases
Improved prediction and risk stratification of major adverse cardiovascular events using an explainable machine learning approach combining plasma biomarkers and traditional risk factors
Cardiovasc Diabetol
Zhang XR, Zhong WF, Liu RY, Huang JL, Fu JX, Gao J, Zhang PD, Liu D, Li ZH, He Y, Zhou H, Li Z
doi: 10.1186/s12933-025-02711-x
ESC 2025
Heart Failure
VICTORIA and VICTOR: Vericiguat reduces the risk of both cardiovascular death and HF hospitalizations, as well as all-cause mortality in a broad population of patients with heart failure
Cardiovascular Risk and Diseases
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies
Ann Intern Med
Saeed A, Mulukutla SR, Thoma F, Lemon L, Koczo A, Reis S, Marroquin O, Kip K
doi: 10.7326/ANNALS-24-00775
Cardiovascular Risk and Diseases
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Lancet Diabetes Endocrinol
Aggarwal R, Bhatt DL, Szarek M, Cannon CP, Leiter LA, Inzucchi SE, Lopes RD, McGuire DK, Lewis JB, Riddle MC, Davies MJ, Banks P, Carroll AK, Scirica BM, Ray KK, Kosiborod MN, Cherney DZI, Udell JA, Verma S, Mason RP, Pitt B, Steg PG
doi: 10.1016/S2213-8587(24)00362-0
Heart, Artery and Coronary DiseasesTherapy and Intervention
Impact of Left Ventricular Function on Outcomes in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
Am Heart J
Pitaro N, Nicolas J, Sartori S, Shneyderman M, Feng Y, Vogel B, Oliva A, Smith KF, Sweeny J, Krishnana P, Gitto M, Kapur V, Muro FMD, Moreno P, Suleman J, Bay B, Hooda A, Sharma R, Krishnamoorthy PM, Kini A, Dangas G, Sharma S, Mehran R
doi: 10.1016/j.ahj.2025.06.017
Cardiovascular Risk and Diseases
Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study
Diabetes Obes Metab
Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J
doi: 10.1111/dom.70214